Share This Article:

Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation

Full-Text HTML XML Download Download as PDF (Size:36KB) PP. 266-267
DOI: 10.4236/wjcd.2013.33042    3,188 Downloads   4,352 Views Citations

ABSTRACT

Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiesterase inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5 (PDE5I) have been used as part of the treatment in certain patients, however, such combination has not been studied or reported before.

Cite this paper

Reyna, J. , Peguero, J. , Escolar, E. , Santana, O. and Lamas, G. (2013) Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation. World Journal of Cardiovascular Diseases, 3, 266-267. doi: 10.4236/wjcd.2013.33042.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.